Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Bladder Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Urothelial Cancer (454)

Urothelial Cancer (454)

›

No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	nadofaragene firadenovec-vncg Sensitive: A1 - Approval nadofaragene firadenovec-vncg Sensitive : A1	nadofaragene firadenovec-vncg Sensitive: A1 - Approval nadofaragene firadenovec-vncg Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2